Patent ID: 6228860
Filing Date: 2001-05-08
Classification: A61K,A61P,C07D,C07F,C07H

Abstract:
A method of treating 3TC.TM.-resistant or FTC-resistant human immunodeficiency virus infections in mammals comprising the step of administering to said mammal a pharmaceutical formulation, the pharmaceutical formulation comprising a compound selected from the group consisting ofa. 2R-hydroxymethyl-4R-(cytosin-1'-yl)-1,3-oxathiolane;b. 2S-hydroxymethyl-4S-(cytosin-1'-yl)-1,3-oxathiolane;c. 2R-hydroxymethyl-4R-(5'-fluorocytosin-1'-yl)-1,3-oxathiolane;d. 2S-hydroxymethyl-4S-(5'-fluorocytosin-1'-yl)-1,3-oxathiolane; ande. pharmaceutically acceptable salts and esters of the foregoing compounds in an amount effective for treating 3TC.TM.-resistant or FTC-resistant human immunodeficiency virus infections, wherein 3TC.TM. is 2R-hydroxmethyl-5S-(cytosin-1'-yl)-1,3-oxathiolane and FTC is 2-hydroxymethyl-5-(5'-fluorocytosin-1'-yl)-1,3-oxathiolane, the pharmaceutical formulation further comprising a pharmaceutically acceptable carrier.